Perspective Therapeutics (CATX) Stock Statistics & Valuation Metrics

Perspective Therapeutics has a market cap or net worth of $360.92M. The enterprise value is $67.36M.

Perspective Therapeutics has 74,262,990 shares outstanding. The number of shares has decreased by -2.65% in one year.

Perspective Therapeutics’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is 3.15%.

The current PE Ratio of Perspective Therapeutics is ―. Perspective Therapeutics’s PEG ratio is -0.06.

In the last 12 months, Perspective Therapeutics had revenue of 0.00 and earned -79.28M in profits. Earnings per share was -1.23.

In the last 12 months, operating cash flow was -58.65M and capital expenditures -53.79M, giving a free cash flow of -112.45M billion.

Perspective Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Perspective Therapeutics upcoming earnings date is Nov 18, 2025, After Close (Confirmed).

Perspective Therapeutics as a current ratio of 12.68, with Debt / Equity ratio of 0.72%

In the past 12 months, Perspective Therapeutics has paid -2.10M in taxes.

Perspective Therapeutics EV to EBITDA ratio is 13.99, with an EV/FCF ratio of -2.01.

Perspective Therapeutics has $191.58M in cash and marketable securities with $1.92M in debt, giving a net cash position of $189.66M billion.

Gross margin is -150.17%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Perspective Therapeutics is $14.44, which is 11.43% higher than the current price. The consensus rating is Strong Buy